World Markets Oncology

World Markets Oncology offers a versatile approach for gaining data, insight and analysis on approved and R&D cancer drugs in nine major country markets. Subscribers receive access to:

• The Oncology Pricing and Clinical Database: 55 sets of data for more than 20,000 approved drugs and R&D drugs for cancer 
• Same-Day Oncology News Analysis: major oncology events by cancer area, drug class, and regulatory profile, plus a weekly oncology milestones bulletin summarizing the week’s analysis 
• Over 200 cancer area, drug class, and regulatory profiles 
• Special Reports on industry events and trends 
• Phone access to our research analysts

Benefits:

World Markets Oncology enables you to:

• Evaluate market opportunities and risks 
• Monitor competitors and customers 
• Make informed decisions 
• Assess the impact of a changing regulatory environment 
• Plan and forecast budgets 
• Stay up to date with recent industry developments and market trends

The Oncology Pricing and Clinical Database 

• Coverage of over 10,000 approved and R&D drugs for oncology and supportive care 
• Global pipeline of pricing, approval, and cost information for medicines in Australia, Canada, France, Germany, Italy, Japan, Spain, the United Kingdom, and the United States 
• 55 sets of data per drug from Phase I through to approval, including: 
  • Average annual cost per drug in each of the approved indications for any marketed drug, accounting for the price, dosing, average use duration, and market presentation 
  • Reimbursement restrictions, with guidance from institutions such as the United Kingdom's National Institutes of Clinical Health and Excellence (NICE), the German Institute for Quality and Efficiency in Healthcare (IQWiG), France's Transparency Commission, Italy's Agenzia Italiana del Farmaco (AIFA), and United States' National Comprehensive Cancer Network (NCCN) 
  • Ex-manufacturing prices 
  • Clinical trial design, endpoints, and results 
  • Approval information, including impending approval dates, expected upcoming filings, new indications, and orphan drug/fast-track designations 
  • Descriptions of all drugs, including experimental drugs 
  • Licensing status 
• Daily updates 
  

Same-Day Oncology Analysis

• Tracking of all major oncology events by cancer area, drug class, and regulatory profile, including: 
  • Regulatory submissions 
  • Price changes 
  • Major conferences 
  • Clinical data 
  • Mergers and acquisitions 
• Weekly Oncology Milestones Bulletin: 
  • Summary of every database update that week 
  • Editorial on the week's key events
    

Cancer Area, Drug Class, and Regulatory Profiles 

• Coverage of over 200 disease areas, drug classes, and regulatory profiles 
• Exclusive information on all significant cancer areas, including: 
  • Standard of care 
  • New drug approvals 
  • Market data 
  • Significant R&D trends 
• Overview of all cancer-related drug classes, including: 
  • Older areas (e.g., plant alkaloids) 
  • Newer areas (e.g., TK inhibitors, HDAC inhibitors) 
  • Non-approved classes (e.g., HSP90 inhibitors) 
• Overview of all major oncology-related regulation and pricing 
  

Special Reports 

• Monthly client-driven special reports on oncology trends 
  

Direct access to our team of analysts

Our expert team provides an independent, fact-based view of the healthcare and pharmaceutical industry, fully supported by our 325+ economists and analysts worldwide with expertise in over 120 industries and 200 countries.

IHS Global Insight is the world leader in economic and financial analysis, forecasting, and market intelligence—with more than 40 years experience and an outstanding record for accuracy.